BPD
MCID: BRN056
MIFTS: 57

Bronchopulmonary Dysplasia (BPD)

Categories: Fetal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Bronchopulmonary Dysplasia

MalaCards integrated aliases for Bronchopulmonary Dysplasia:

Name: Bronchopulmonary Dysplasia 52 58 54 37 62 71
Bpd 52 58

Characteristics:

Orphanet epidemiological data:

58
bronchopulmonary dysplasia
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Infancy,Neonatal; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare respiratory diseases
Developmental anomalies during embryogenesis


External Ids:

MESH via Orphanet 44 D001997
ICD10 via Orphanet 33 P27.1
UMLS via Orphanet 72 C0006287
Orphanet 58 ORPHA70589
UMLS 71 C0006287

Summaries for Bronchopulmonary Dysplasia

PubMed Health : 62 About bronchopulmonary dysplasia: Bronchopulmonary (BRONG-ko-PUL-mo-NAR-e) dysplasia (dis-PLA-ze-ah), or BPD, is a serious lung condition that affects infants. BPD mostly affects premature infants who need oxygen therapy (oxygen given through nasal prongs, a mask, or a breathing tube). Most infants who develop BPD are born more than 10 weeks before their due dates, weigh less than 2 pounds (about 1,000 grams) at birth, and have breathing problems. Infections that occur before or shortly after birth also can contribute to BPD. Some infants who have BPD may need long-term breathing support from nasal continuous positive airway pressure (NCPAP) machines or ventilators.

MalaCards based summary : Bronchopulmonary Dysplasia, also known as bpd, is related to bronchial disease and cerebral palsy. An important gene associated with Bronchopulmonary Dysplasia is SFTPB (Surfactant Protein B), and among its related pathways/superpathways are Innate Immune System and NF-KappaB Family Pathway. The drugs Procaterol and Budesonide have been mentioned in the context of this disorder. Affiliated tissues include Lung, and related phenotypes are emphysema and cough

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 70589 Definition Bronchopulmonary dysplasia is a chronic respiratory disease that results from complications related to lung injury during the treatment of infant acute respiratory distress syndrome (see these terms) in low-birth-weight premature infants or from abnormal lung development in older infants. Clinical signs are tachypnea, tachycardia and signs of respiratory distress such as intercostal recession, grunting and nasal flaring. Visit the Orphanet disease page for more resources.

Wikipedia : 74 Bronchopulmonary dysplasia (BPD; formerly chronic lung disease of infancy) is a chronic lung disease in... more...

Related Diseases for Bronchopulmonary Dysplasia

Diseases related to Bronchopulmonary Dysplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 283)
# Related Disease Score Top Affiliating Genes
1 bronchial disease 31.9 RNASE3 ELANE CXCL8
2 cerebral palsy 30.9 TIMP1 SOD1 CXCL8
3 gastroesophageal reflux 30.7 IL1RN ELANE CXCL8
4 bronchiolitis 30.7 SCGB1A1 RNASE3 CXCL8
5 neonatal respiratory failure 30.7 SFTPB SCGB1A1
6 pulmonary edema 30.6 SCGB1A1 FGF7 CXCL8
7 newborn respiratory distress syndrome 30.6 SFTPB SCGB1A1 FGF7 ELANE CXCL8
8 chorioamnionitis 30.5 IL1RN FLT1 ELANE CXCL8
9 pulmonary fibrosis 30.3 TIMP1 FGF7 ELANE CXCL8
10 interstitial lung disease 30.2 TIMP1 SFTPB CXCL8
11 bronchitis 30.2 RNASE3 ELANE CXCL8
12 bronchiolitis obliterans 30.1 TIMP1 SCGB1A1 CXCL8
13 pre-eclampsia 30.1 SOD1 SELL FLT1 CXCL8
14 bacterial infectious disease 30.0 SELL IL1RN ELANE CXCL8
15 bacterial sepsis 30.0 IL1RN ELANE CXCL8
16 adult respiratory distress syndrome 30.0 SFTPB FGF7 ELANE CXCL8
17 allergic asthma 30.0 SCGB1A1 RNASE3 CXCL8
18 diaphragmatic hernia, congenital 29.9 SFTPB FGF7 FGF10
19 rhinitis 29.8 SCGB1A1 RNASE3 CXCL8
20 pneumonia 29.8 SFTPB SELL SCGB1A1 IL1RN ELANE CXCL8
21 gastroenteritis 29.8 RNASE3 IL1RN CXCL8
22 extrinsic allergic alveolitis 29.7 SOD1 SELL ELANE CXCL8
23 pulmonary emphysema 29.6 TIMP1 FGF7 ELANE CXCL8
24 lung disease 29.5 TXN SOD1 SFTPB SCGB1A1 RNASE3 FGF7
25 proteasome-associated autoinflammatory syndrome 1 29.5 SELL RNASE3 IL1RN ELANE CXCL8
26 otitis media 29.4 RNASE3 IL1RN ELANE CXCL8
27 allergic rhinitis 29.4 SCGB1A1 RNASE3 CXCL8
28 respiratory failure 29.3 TIMP1 SOD1 SFTPB SCGB1A1 RNASE3 IL1RN
29 cataract 28.9 TXN TIMP1 SOD1 IL1RN CXCL8
30 pulmonary disease, chronic obstructive 28.7 TXN TIMP1 SFTPB SCGB1A1 RNASE3 ELANE
31 pulmonary fibrosis, idiopathic 28.6 TIMP1 SFTPB SCGB1A1 IL1RN FGF7 ELANE
32 asthma 28.5 TIMP1 SELL SCGB1A1 RNASE3 IL1RN ELANE
33 borderline personality disorder 11.8
34 pulmonary hypertension, neonatal 11.3
35 pulmonary hypertension 10.9
36 personality disorder 10.9
37 patent ductus arteriosus 1 10.9
38 exudative vitreoretinopathy 1 10.7
39 respiratory distress syndrome in premature infants 10.7
40 enterocolitis 10.6
41 perinatal necrotizing enterocolitis 10.6
42 periventricular leukomalacia 10.5
43 vascular disease 10.5
44 pneumothorax 10.5
45 avoidant personality disorder 10.5
46 pouchitis 10.4 IL1RN CXCL8
47 interstitial emphysema 10.4
48 toxicodendron dermatitis 10.4 SELL CXCL8
49 paraquat lung 10.4 SFTPB SCGB1A1
50 pustulosis of palm and sole 10.4 IL1RN CXCL8

Graphical network of the top 20 diseases related to Bronchopulmonary Dysplasia:



Diseases related to Bronchopulmonary Dysplasia

Symptoms & Phenotypes for Bronchopulmonary Dysplasia

Human phenotypes related to Bronchopulmonary Dysplasia:

58 31 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 emphysema 58 31 hallmark (90%) Very frequent (99-80%) HP:0002097
2 cough 58 31 hallmark (90%) Very frequent (99-80%) HP:0012735
3 premature birth 58 31 hallmark (90%) Very frequent (99-80%) HP:0001622
4 respiratory failure requiring assisted ventilation 58 31 hallmark (90%) Very frequent (99-80%) HP:0004887
5 respiratory distress 58 31 hallmark (90%) Very frequent (99-80%) HP:0002098
6 small for gestational age 58 31 hallmark (90%) Very frequent (99-80%) HP:0001518
7 chronic lung disease 58 31 hallmark (90%) Very frequent (99-80%) HP:0006528
8 hyperoxemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0012419
9 sleep disturbance 58 31 frequent (33%) Frequent (79-30%) HP:0002360
10 diaphragmatic paralysis 58 31 frequent (33%) Frequent (79-30%) HP:0006597
11 central apnea 58 31 frequent (33%) Frequent (79-30%) HP:0002871
12 exercise intolerance 58 31 frequent (33%) Frequent (79-30%) HP:0003546
13 right ventricular hypertrophy 58 31 frequent (33%) Frequent (79-30%) HP:0001667
14 right ventricular failure 58 31 frequent (33%) Frequent (79-30%) HP:0001708
15 wheezing 58 31 frequent (33%) Frequent (79-30%) HP:0030828
16 atelectasis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100750
17 tracheobronchomalacia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002786
18 pulmonary sequestration 58 31 occasional (7.5%) Occasional (29-5%) HP:0100632
19 dyspnea 58 Very frequent (99-80%)
20 abnormal lung morphology 58 Very frequent (99-80%)
21 abnormal respiratory system morphology 58 Frequent (79-30%)
22 functional respiratory abnormality 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Bronchopulmonary Dysplasia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10 ELANE FGF10 FGF7 FLT1 IL1RN RBP4
2 hematopoietic system MP:0005397 9.97 ELANE FGF10 FGF7 FLT1 IL1RN SCGB1A1
3 immune system MP:0005387 9.81 ELANE FGF10 FGF7 FLT1 IL1RN SCGB1A1
4 mortality/aging MP:0010768 9.65 ELANE FGF10 FLT1 IL1RN SCGB1A1 SELL
5 reproductive system MP:0005389 9.23 FGF10 FGF7 FLT1 IL1RN RBP4 SELL

Drugs & Therapeutics for Bronchopulmonary Dysplasia

PubMed Health treatment related to Bronchopulmonary Dysplasia: 62

If your doctor thinks you're going to give birth too early, he or she may give you injections of a corticosteroid medicine. The medicine can speed up surfactant production in your baby. Surfactant is a liquid that coats the inside of the lungs . It helps keep the lungs open so your infant can breathe in air once he or she is born. Corticosteroids also can help your baby's lungs , brain , and kidneys develop more quickly while he or she is in the womb . Premature babies who have very low birth weights also might be given corticosteroids within the first few days of birth. Doctors sometimes prescribe inhaled nitric oxide shortly after birth for babies who have very low birth weights. This treatment can help improve the babies' lung function. These preventive measures may help reduce infants' risk of respiratory distress syndrome (RDS), which can lead to BPD.

Drugs for Bronchopulmonary Dysplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 277)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Procaterol Approved, Investigational Phase 4 72332-33-3 688561
2
Budesonide Approved Phase 4 51333-22-3 63006 5281004
3
Zinc Approved, Investigational Phase 4 7440-66-6 32051
4
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
5
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
6
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
7 Vitamins Phase 4
8 Calciferol Phase 4
9 Adrenergic Agonists Phase 4
10 Antibodies Phase 4
11 Immunoglobulins Phase 4
12 Immunoglobulins, Intravenous Phase 4
13 Lactoferrin Phase 4
14 Vaccines Phase 4
15 Immunologic Factors Phase 4
16 Anti-Infective Agents Phase 4
17 Anti-Bacterial Agents Phase 4
18 Hormone Antagonists Phase 4
19 Hormones Phase 4
20 Anti-Asthmatic Agents Phase 4
21 Bronchodilator Agents Phase 4
22 glucocorticoids Phase 4
23 Anti-Inflammatory Agents Phase 4
24 Antibiotics, Antitubercular Phase 4
25 Gentamicins Phase 4
26 Dermatologic Agents Phase 4
27
Clarithromycin Approved Phase 3 81103-11-9 84029
28
Furosemide Approved, Vet_approved Phase 2, Phase 3 54-31-9 3440
29
Spironolactone Approved Phase 2, Phase 3 52-01-7, 1952-01-7 5833
30
Chlorothiazide Approved, Vet_approved Phase 2, Phase 3 58-94-6 2720
31
Nitric Oxide Approved Phase 3 10102-43-9 145068
32
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
33
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
34
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
35 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
36
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
37
Ibuprofen Approved Phase 2, Phase 3 15687-27-1 3672
38
Calfactant Approved Phase 3 183325-78-2
39
Palivizumab Approved, Investigational Phase 2, Phase 3 188039-54-5
40
Nitrous oxide Approved, Vet_approved Phase 3 10024-97-2 948
41
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
42
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
43
Benzyl alcohol Approved Phase 3 100-51-6 244
44
Ethanol Approved Phase 3 64-17-5 702
45
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
46
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
47
Cysteine Approved, Nutraceutical Phase 2, Phase 3 52-90-4 5862
48
Ergocalciferol Approved, Nutraceutical Phase 2, Phase 3 50-14-6 5280793
49
Vitamin D3 Approved, Nutraceutical Phase 2, Phase 3 67-97-0 5280795 6221
50
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 68-26-8, 11103-57-4 9904001 445354

Interventional clinical trials:

(show top 50) (show all 381)
# Name Status NCT ID Phase Drugs
1 Early Administration of Surfactant in Spontaneous Breathing (TAKE CARE) Versus InSurE (Intubation, Surfactant, Extubation) : A Pilot Study Unknown status NCT01329432 Phase 4
2 Early Bubble CPAP (EBCPAP) in Very Low Birth Weight Infants (VLBWI) Unknown status NCT00368680 Phase 4
3 Prevention of Chronic Lung Disease (CLD) in Preterm Infants -A New Therapeutic Regimen Unknown status NCT00883532 Phase 4 budesonide;surfactant and air (placebo)
4 THE EFFECT OF SUSTAINED LUNG INFLATION MANEUVER APPLIED THROUGH NASAL PRONG ON EARLY AND LATE RESPIRATORY MORBIDITIES IN PRETERM INFANTS Unknown status NCT02887924 Phase 4
5 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia (BPD). Completed NCT00926276 Phase 4
6 Albuterol Dose-Response on Pulmonary Function Testing in Preterm Infants at Risk of Bronchopulmonary Dysplasia Completed NCT02447250 Phase 4 Varied albuterol dose response
7 Randomized Clinical Trial: Use of Azithromycin to Prevent Lung Damage in Preterm Newborns Under Mechanical Ventilation Completed NCT03485703 Phase 4 Azithromycin;Placebo
8 Multi-dose Vitamin D Supplementation in Preterm Infants Completed NCT02941185 Phase 4 Devit-3 Oral Drop
9 Systematic Randomized , Single Blinded, Placebo-Controlled Trial of Early Versus Late Lactoferrin in Prevention of Neonatal Sepsis Completed NCT02959229 Phase 4 Lactoferrin;Placebo (for Lactoferrin)
10 Prevention of RSV Infections in Bone Marrow Transplant Recipients Completed NCT00001903 Phase 4 RSV Polyclonal Immunoglobulin
11 Randomized Evaluation of the Use of Plastic Bags to Prevent Neonatal Hypothermia in Developing Countries-Part IV Completed NCT01604447 Phase 4
12 A Randomized Trial to Evaluate the Use of Plastic Bags in Preventing and Treating Hypothermia in Neonates in Developing Countries Completed NCT01403623 Phase 4
13 Synchronized Intermittent Mandatory Ventilation (SIMV) Versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) In Preterm Infants With Respiratory Distress Completed NCT00486850 Phase 4
14 Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome. Recruiting NCT03521063 Phase 4 Budesonide;Poractant Alfa;Saline
15 A Randomized, Placebo-controlled Trial of Early Caffeine in Preterm Neonates Recruiting NCT03086473 Phase 4 Caffeine Citrate;Placebo (Normal Saline)
16 Exogenous Surfactant in Very Preterm Neonates Presenting With Severe Respiratory Distress in Prevention of Bronchopulmonary Dysplasia Active, not recruiting NCT01039285 Phase 4 Curosurf
17 Multicentre Randomised Controlled Trial of Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on Continuous Positive Airways Pressure Active, not recruiting NCT02140580 Phase 4
18 Oral Zinc Supplementation Improving Growth and Reducing Morbidity on Very Low Birth Weight Infant Not yet recruiting NCT04050488 Phase 4 Zinc Sulfate;Placebos
19 Routine Administration of Surfactant/Budesonide to Prevent BPD in VLBW With RDS-A Double Blind Study Not yet recruiting NCT03275415 Phase 4 budesonide;Saline
20 NICU Antibiotics and Outcomes Trial Not yet recruiting NCT03997266 Phase 4 Ampicillin;Gentamycin;Normal saline
21 Impact of Early Postnatal Sodium Supplementation on Weight Gain in Very Low Birth Weight Infants Terminated NCT01795638 Phase 4 Sodium chloride;Placebo
22 Rate of Bronchopulmonary Dysplasia in Preterms Neonates Less Than 29 Weeks' Gestational Age and / or With Birth Weight Less Than 1000 g: a Double Blind Randomized Controlled Multicenter Trial Comparing SMOFlipid and Medialipide Withdrawn NCT02853253 Phase 4
23 Prophylaxis of Bronchopulmonary Dysplasia With Clarithromycin Unknown status NCT01652118 Phase 3 clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia;Saline
24 Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia: A Study in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide Unknown status NCT01022580 Phase 3 Infasurf surfactant (ONY, Inc.)
25 Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease Unknown status NCT01721655 Phase 2, Phase 3 Spironolactone;Placebo
26 Use of Orotracheal CPAP ( Gregory System) for Treatment of Respiratory Failure in Newborns Unknown status NCT01379820 Phase 2, Phase 3
27 Evaluating the Efficacy and Safety of an Innovative and Affordable Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates: a Multi-site Randomized Clinical Trial Unknown status NCT02774044 Phase 2, Phase 3 Cadisurf;Survanta
28 Effect of Cysteine Supplementation on Glutathione Production in Critically Ill Neonates Unknown status NCT00254176 Phase 2, Phase 3
29 Inhaled Nitric Oxide to Prevent and Treat Bronchopulmonary Dysplasia in Preterm Infants Completed NCT01503801 Phase 2, Phase 3 Nitric Oxide
30 Phase III Randomized, Double-Blind Study of Dexamethasone Vs Dexamethasone/Methylprednisolone Vs Placebo for Bronchopulmonary Dysplasia Completed NCT00004785 Phase 3 dexamethasone;methylprednisolone
31 Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth Completed NCT00931632 Phase 3 Inhaled Nitric Oxide;Placebo
32 Inhaled Beclomethasone to Prevent Chronic Lung Disease Completed NCT00000576 Phase 3 beclomethasone
33 A Randomized Controlled Trial of Two Hemoglobin Thresholds for Transfusion in Newborns <1000g Birth Weight Completed NCT00182390 Phase 3
34 Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide Completed NCT00569530 Phase 3 Infasurf (ONY Inc.);Sham
35 A Prospective, Multicenter, Open-label, Non-comparative Study of Safety and Efficacy of Synagis in Children at High Risk of Severe Respiratory Syncytial Virus Infection in the Russian Federation Completed NCT01006629 Phase 2, Phase 3
36 Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia Completed NCT01035190 Phase 3 Budesonide
37 Efficacy and Safety of NIPPV to Increase Survival Without Bronchopulmonary Dysplasia in Extremely Low Birth Weight Infants Completed NCT00433212 Phase 3
38 High Frequency Ventilation in Premature Infants (HIFI) Completed NCT00000567 Phase 3
39 Early Prevention of Broncho-pulmonary Dysplasia and Neonatal Mortality in Very Preterm Infants Using Low Dose of Hydrocortisone: a Randomized Controlled Trial Completed NCT00623740 Phase 3 hydrocortisone;placebo
40 Inhaled NO in Prevention of Chronic Lung Disease Completed NCT00000548 Phase 3
41 Efficacy and Safety of Exosurf Neonatal and Survanta for the Treatment of Respiratory Distress Syndrome Completed NCT01203358 Phase 2, Phase 3 Exosurf;Survanta
42 Effect of Early Use of Caffeine Citrate in Preterm Neonates Needing Respiratory Support. Completed NCT04001712 Phase 3 Caffeine Citrate
43 A Prospective, International, Multicenter, Open-Label, Non-Controlled Study of Safety and Effectiveness of Palivizumab, in Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus Completed NCT02968173 Phase 3 Palivizumab
44 Human Surfactant Treatment of Respiratory Distress Syndrome Bicenter Trial Completed NCT00000570 Phase 3 pulmonary surfactant
45 Phase 3 Multicenter, Randomized, Open Label Trial of a New Low Cost Animal Extracted Surfactant to Treat Respiratory Distress Syndrome in Preterm Infants Completed NCT02305160 Phase 2, Phase 3 Butantan;Control
46 L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Transient Hypothyroxinemia of Prematurity: a Prospective Randomized Double-blind Trial Completed NCT01306227 Phase 3 L-Thyroxine;water
47 Inhaled NO for the Prevention of Chronic Lung Disease Completed NCT00006401 Phase 3 iNO
48 A Randomized, Controlled Trial of Synchronized Nasal Intermittent Positive Pressure Ventilation Versus Nasal Continuous Positive Airway Pressure Using the Infant Flow Advance to Facilitate Successful Extubation in Premature Infants. Completed NCT00188968 Phase 3
49 Early Vitamin D Supplementation for Prevention of Respiratory Morbidity in Extremely Preterm Infants: A Randomized Clinical Trial Completed NCT01600430 Phase 2, Phase 3
50 Randomized Comparison of Two Models of Post-NICU Care for Preterm Infants With Neonatal Chronic Lung Disease Completed NCT00314431 Phase 3

Search NIH Clinical Center for Bronchopulmonary Dysplasia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bronchopulmonary Dysplasia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bronchopulmonary Dysplasia:
PNEUMOSTEM, cord blood-derived mesenchymal stem cells for bronchopulmonary dysplasia

Genetic Tests for Bronchopulmonary Dysplasia

Anatomical Context for Bronchopulmonary Dysplasia

MalaCards organs/tissues related to Bronchopulmonary Dysplasia:

40
Lung, Endothelial, Brain, Testes, Bone, Heart, Fetal Lung
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Bronchopulmonary Dysplasia:
# Tissue Anatomical CompartmentCell Relevance
1 Lung Pulmonary Capillary Plexus Affected by disease
2 Lung Alveoli Alveolar Epithelial Type 1 Cells Affected by disease, potential therapeutic candidate
3 Lung Alveoli Alveolar Epithelial Type 2 Cells Affected by disease, potential therapeutic candidate

Publications for Bronchopulmonary Dysplasia

Articles related to Bronchopulmonary Dysplasia:

(show top 50) (show all 6792)
# Title Authors PMID Year
1
Cord blood Clara cell protein CC16 predicts the development of bronchopulmonary dysplasia. 61 54
18521627 2008
2
Clara cell secretory protein (CC16) as a peripheral blood biomarker of lung injury in ventilated preterm neonates. 54 61
18521628 2008
3
Gastrin-releasing peptide, immune responses, and lung disease. 54 61
19076373 2008
4
FGF-10 is decreased in bronchopulmonary dysplasia and suppressed by Toll-like receptor activation. 54 61
17071719 2007
5
Selectin polymorphisms and perinatal morbidity in low-birthweight infants. 54 61
16982492 2006
6
Lower parathyroid hormone-related protein content of tracheal aspirates in very low birth weight infants who develop bronchopulmonary dysplasia. 61 54
16864707 2006
7
Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. 61 54
16856062 2006
8
The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome. 54 61
15774846 2005
9
Erythrocyte Cu/Zn superoxide dismutase activity in preterm infants with and without bronchopulmonary dysplasia. 61 54
15767740 2005
10
Distribution of antioxidant enzymes in developing human lung, respiratory distress syndrome, and bronchopulmonary dysplasia. 54 61
15314090 2004
11
Neutrophil and monocyte adhesion molecules in bronchopulmonary dysplasia, and effects of corticosteroids. 54 61
14711863 2004
12
Interleukin-10 inhibits proinflammatory chemokine release by neutrophils of the newborn without suppression of nuclear factor-kappa B. 54 61
12788980 2003
13
Soluble E-selectin, soluble L-selectin and soluble ICAM-1 in bronchopulmonary dysplasia, and changes with dexamethasone. 54 61
12612222 2003
14
Roles for insulin-like growth factor I and transforming growth factor-beta in fibrotic lung disease. 54 61
12475802 2002
15
Secretoglobins SCGB3A1 and SCGB3A2 define secretory cell subsets in mouse and human airways. 54 61
12406855 2002
16
High concentrations of keratinocyte growth factor in airways of premature infants predicted absence of bronchopulmonary dysplasia. 61 54
12016100 2002
17
Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. 61 54
11734454 2001
18
Monocyte chemoattractant protein-1 and interleukin-8 are increased in bronchopulmonary dysplasia: relation to isolation of Ureaplasma urealyticum. 61 54
11478413 2001
19
Superoxide dismutase for preventing chronic lung disease in mechanically ventilated preterm infants. 54 61
11279743 2001
20
Effects of early inhaled beclomethasone therapy on tracheal aspirate inflammatory mediators IL-8 and IL-1ra in ventilated preterm infants at risk for bronchopulmonary dysplasia. 54 61
11015126 2000
21
An alternatively spliced surfactant protein B mRNA in normal human lung: disease implication. 54 61
10493923 1999
22
Hyperoxia induces thioredoxin and thioredoxin reductase gene expression in lungs of premature baboons with respiratory distress and bronchopulmonary dysplasia. 61 54
10424622 1999
23
Effect of oxygen on lung superoxide dismutase activities in premature baboons with bronchopulmonary dysplasia. 54 61
9887057 1999
24
Elevated interleukin-8 concentrations in amniotic fluid of mothers whose neonates subsequently develop bronchopulmonary dysplasia. 54 61
9605441 1998
25
L-selectin expression on polymorphonuclear leukocytes and monocytes in premature infants: reduced expression after dexamethasone treatment for bronchopulmonary dysplasia. 61 54
9470000 1998
26
Cromolyn sodium prophylaxis inhibits pulmonary proinflammatory cytokines in infants at high risk for bronchopulmonary dysplasia. 54 61
9372670 1997
27
Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia. 61 54
9407566 1997
28
Airway lesions and superoxide dismutase (SOD) distribution in bronchopulmonary dysplasia (BPD). 61 54
9642974 1997
29
Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. 61 54
9369827 1997
30
Eosinophil cationic protein in tracheal aspirates of preterm infants with bronchopulmonary dysplasia. 61 54
9202617 1997
31
Altered platelet-activating factor levels and acetylhydrolase activities are associated with increasing severity of bronchopulmonary dysplasia. 61 54
8853062 1996
32
Elevated cytokine levels in tracheobronchial aspirate fluids from ventilator treated neonates with bronchopulmonary dysplasia. 61 54
8775225 1996
33
Use of the intramuscular relative-dose-response test to predict bronchopulmonary dysplasia in premature infants. 61 54
8604659 1996
34
Secretory leukocyte protease inhibitor and lung inflammation in developing bronchopulmonary dysplasia. 54 61
7913723 1994
35
Proteinase-antiproteinase balance in tracheal aspirates from neonates. 54 61
7909297 1994
36
Pulmonary endocrine cells in infancy and childhood. 54 61
2014192 1991
37
Plasma retinol-binding protein response to vitamin A administration in infants susceptible to bronchopulmonary dysplasia. 61 54
2108233 1990
38
Individualising care in severe bronchopulmonary dysplasia: a series of N-of-1 trials comparing transpyloric and gastric feeding. 61
31685527 2020
39
Chemical shift of 129 Xe dissolved in red blood cells: Application to a rat model of bronchopulmonary dysplasia. 61
31814155 2020
40
Cognitive skills in preterm infants with bronchopulmonary dysplasia at 1 year adjusted and 2 years chronological age. 61
30513032 2020
41
Autophagy inducer activates Nrf2-ARE pathway to attenuate aberrant alveolarization in neonatal rats with bronchopulmonary dysplasia. 61
32298739 2020
42
Assessment of the G-ROP study criteria for predicting retinopathy of prematurity: results from a tertiary centre in Turkey. 61
32200507 2020
43
Core outcomes in neonatology: development of a core outcome set for neonatal research. 61
31732683 2020
44
The effects of latency period in PPROM cases managed expectantly. 61
32089027 2020
45
The effects of omega-3 fatty acids on the newborn rat hyperoxic lung injury. 61
30614311 2020
46
Advancements in understanding the role of lysophospholipids and their receptors in lung disorders including bronchopulmonary dysplasia. 61
32169655 2020
47
Analysis of interleukins 6, 8, 10 and 17 in the lungs of premature neonates with bronchopulmonary dysplasia. 61
32403004 2020
48
Management of bronchopulmonary dysplasia in Japan: A 10-year nationwide survey. 61
31843363 2020
49
Using Experimental Models to Identify Pathogenic Pathways and Putative Disease Management Targets in Bronchopulmonary Dysplasia. 61
32485712 2020
50
Effect of a new respiratory care bundle on bronchopulmonary dysplasia in preterm neonates. 61
32488737 2020

Variations for Bronchopulmonary Dysplasia

Expression for Bronchopulmonary Dysplasia

Search GEO for disease gene expression data for Bronchopulmonary Dysplasia.

Pathways for Bronchopulmonary Dysplasia

Pathways related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.57 TXN TIMP1 SELL RNASE3 IL1RN FGF7
2
Show member pathways
12.29 TIMP1 FLT1 FGF7 FGF10
3
Show member pathways
12 TIMP1 FLT1 FGF7 FGF10
4
Show member pathways
11.23 TIMP1 FLT1 FGF7 FGF10 CXCL8
5 11.13 TIMP1 FGF7 CXCL8
6 10.82 TIMP1 IL1RN CXCL8
7 10.56 TIMP1 FLT1 FGF7 FGF10 CXCL8

GO Terms for Bronchopulmonary Dysplasia

Cellular components related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.8 TXN TIMP1 SOD1 SCGB1A1 RBP4 IL1RN
2 extracellular space GO:0005615 9.7 TIMP1 SOD1 SFTPB SCGB1A1 RNASE3 RBP4
3 extracellular region GO:0005576 9.44 TXN TIMP1 SOD1 SFTPB SCGB1A1 RNASE3
4 secretory granule GO:0030141 9.33 SOD1 SCGB1A1 ELANE

Biological processes related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 9.72 TXN FGF7 FGF10
2 response to lipopolysaccharide GO:0032496 9.7 SCGB1A1 FGF10 ELANE
3 chemotaxis GO:0006935 9.67 FLT1 FGF10 CXCL8
4 hair follicle morphogenesis GO:0031069 9.54 FGF7 FGF10
5 protein localization to cell surface GO:0034394 9.51 FGF7 FGF10
6 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.48 FLT1 FGF10
7 embryonic digestive tract development GO:0048566 9.46 FGF10 CXCL8
8 induction of positive chemotaxis GO:0050930 9.43 FGF10 CXCL8
9 response to organic substance GO:0010033 9.43 TIMP1 SOD1 SCGB1A1
10 positive regulation of keratinocyte proliferation GO:0010838 9.4 FGF7 FGF10
11 branching involved in salivary gland morphogenesis GO:0060445 9.37 FGF7 FGF10
12 positive regulation of keratinocyte migration GO:0051549 9.32 FGF7 FGF10
13 regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling GO:0060665 9.16 FGF7 FGF10
14 secretion by lung epithelial cell involved in lung growth GO:0061033 8.96 FGF7 FGF10
15 female genitalia morphogenesis GO:0048807 8.62 RBP4 FGF10

Molecular functions related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.43 TIMP1 FGF7 FGF10
2 fibroblast growth factor receptor binding GO:0005104 9.16 FGF7 FGF10
3 protease binding GO:0002020 9.13 TIMP1 SELL ELANE
4 heparin binding GO:0008201 8.92 SELL FGF7 FGF10 ELANE

Sources for Bronchopulmonary Dysplasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....